Abstract
Injectable analogs of GLP-1 and GLP-2 are commonly used for the treatment of obesity type 2diabetes mellitus (T2DM). Currently, applications of these hormones in the form of the peptideitself are limited due to their short half-life. The oral administration of a therapeutic peptide (TP) represents a significant biomedical advancement, yet it faces challenges related to gastrointestinalins…